Effect of mango leaf on diabetes on lipid profiles

Effects of Mangifera indica extract supplement on metabolic status in type 2 diabetic patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180923041093N2

Enrollment

Registered

2019-10-12

Start date

2019-11-21

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: Mango leaf extract 500 mg, twice daily, for 45 days. Intervention 2: Control group: Placebo 500 mg twice daily for 45 days.

Eligibility

Sex/Gender

All

Age

25 Years to 60 Years

Inclusion criteria

Inclusion criteria: Type 1 Diabetes According to the World Health Organization's online guide from 6 months ago Taking blood sugar lowering drugs

Exclusion criteria

Exclusion criteria: Changes in diabetes medications from 2 months before the study Insulin consumption Smoking Pregnancy Use of herbal medications Lactation Gastrointestinal and liver problems Hormonal problems such as thyroid dysfunction Cardiac problems Medications that interfere with blood sugar and lipid levels such as non-inflammatory drugs Steroid

Design outcomes

Primary

Measure	Time frame
Body mass index. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Weight to square height ratio.;Fasting blood sugar. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting serum Glucose concentration in mg/dl by kit.;2 hours post prandial. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting serum Glucose concentration in mg/dl by kit.;Fasting Insulin. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting serum Insulin concentration in µU/ml by kit.;Serum Teriglycerid. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting serum Teriglycerid concentration in mg/dl by kit.;Serum cholestrol. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting Serum cholestrol concentration in mg/dl by kit.;LDL Cholestrol. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting Serum HDL Cholestrol concentration in mg/dl, calculating by Friedewald formula.;HDL Cholestrol. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting Serum HDL Cholestrol concentration in mg/dl by kit.	—

Measure

Time frame

Body mass index. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Weight to square height ratio.;Fasting blood sugar. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting serum Glucose concentration in mg/dl by kit.;2 hours post prandial. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting serum Glucose concentration in mg/dl by kit.;Fasting Insulin. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting serum Insulin concentration in µU/ml by kit.;Serum Teriglycerid. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting serum Teriglycerid concentration in mg/dl by kit.;Serum cholestrol. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting Serum cholestrol concentration in mg/dl by kit.;LDL Cholestrol. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting Serum HDL Cholestrol concentration in mg/dl, calculating by Friedewald formula.;HDL Cholestrol. Timepoint: Baseline and 45 days after the intervention. Method of measurement: Fasting Serum HDL Cholestrol concentration in mg/dl by kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Azimi

Kerman University of Medical Sciences

dr.azimm@gmail.com+98 34 3211 0860

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026